AEHR vs. CAMT: Which Semiconductor Equipment Stock Is the Better Bet?

Aehr Test Systems is presented as the more compelling semiconductor-equipment investment, forecasting fiscal 2027 revenue of $130-$150 million, implying roughly 160%-200% growth, supported by a record $100.6 million effective backlog and accelerating AI burn-in demand. AI processors represented about 71% of AEHR's fiscal 2026 revenue, while its Q4 revenue rose 33.7% year over year and fiscal 2027 EPS consensus increased $0.04 to $0.74. Camtek remains well positioned in AI advanced packaging, with more than $600 million of year-to-date orders—about 80% tied to advanced packaging—and over $105 million of 2027 delivery orders, but AEHR offers greater projected earnings growth despite its higher 19.81x forward P/S valuation versus CAMT's 9.88x.

Analysis

The relevant distinction is not AI exposure but revenue quality. AEHR’s economics hinge on conversion of a concentrated, qualification-stage customer pipeline into repeat production tool orders; a single delayed processor ramp can create material quarterly volatility and collapse the valuation premium. CAMT monetizes process complexity across OSATs and memory suppliers, making its demand less dependent on any one chip design win and more directly levered to packaging content per package.

Near term, AEHR’s elevated sales multiple leaves little room for a guide that merely confirms rather than raises the implied growth trajectory. The key 1-3 month catalyst is evidence that the pilot customer becomes a production customer and that backlog converts on schedule; absent this, the market is likely to reassess both utilization and the durability of burn-in intensity. CAMT’s order visibility should support estimates over the next 12-18 months, but working-capital expansion could mute free-cash-flow conversion and China restrictions remain the principal downside asymmetry.

The contrarian view is that burn-in may become a manufacturing bottleneck only temporarily: better chip binning, architectural redundancy and improved yields can reduce test intensity per unit after initial AI-platform ramps. Conversely, advanced-package inspection intensity is structurally rising as HBM stacks and chiplet counts increase, benefiting CAMT and peers such as KLAC and ONTO even if AI unit demand moderates. The article’s revenue-growth comparison therefore overweights AEHR’s base-effect optics relative to CAMT’s broader, more repeatable content opportunity.

Key Decisions for Investors

• Prefer a 6-12 month long CAMT / short AEHR pair, sized beta-neutral: CAMT offers diversified advanced-packaging content at roughly half AEHR’s forward sales multiple, while AEHR is vulnerable to a production-validation delay. Target 15-25% relative return; exit if AEHR reports a second material production customer or CAMT’s order conversion weakens.
• Do not chase AEHR after momentum; establish only following verified production-order disclosure and a maintained or increased annual outlook. Use a 10-12% position stop or exit on backlog declining sequentially without replacement orders, as the premium multiple can compress rapidly.
• For broader structural exposure, favor KLAC or ONTO over the next 12-18 months as more liquid beneficiaries of rising inspection/metrology steps in HBM and advanced packaging; this reduces single-customer and small-cap execution risk embedded in AEHR.
• Monitor CAMT receivables, inventory turns and China revenue commentary at the next results. A material deterioration in cash conversion or new export-control constraints would invalidate the long leg despite order-book strength.